RESEARCH COMMUNICATIONS OF THE 28th ECVIM-CA CONGRESS

Diabetic cats (diagnosed <6 months) were recruited for a 6‐month, double‐blinded, randomised, placebo‐controlled clinical trial assessing the effect of once monthly exenatide extended release (EER; Bydureon, AstraZeneca) injections on glycaemic control and BCF. Cats were excluded if screening identified relevant co‐morbid conditions. Cats were treated with protamine zinc insulin (ProZinc, Boehringer Ingelheim), fed a low‐carbohydrate diet and randomised to EER (0.13mg/kg SQ q 27‐32 days) or placebo (saline). Diabetic control and BCF were assessed using fructosamine, and insulin peak response (IPR) and total insulin secretion (TIS) calculated from glucagon stimulation tests (insulin at baseline, 15 and 60 mins post 20ug/kg IV glucagon), respectively. Enrolment body condition score (BCS) and fructosamine were compared between groups (t‐test). Linear mixed effects modelling assessed the effect of treatment group, trial timepoint and enrolment BCS (> or <5/9) on glycaemic control and BCF (significance p<0.05).